Sourcing Blockbuster Oncology Products for Clinical Trial Supply
XTalks
JANUARY 29, 2021
Several oncology products now have “blockbuster” status where sales exceed $1 billion annually. This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster products. Keytruda (Pembrolizumab) and Opdivo (Nivolumab).
Let's personalize your content